Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full year 2025 and multi-year ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its guidance for 2025. The stock gained another 1.8% in after-hours trading. HALO also maintained its full-year ...

Halozyme Therapeutics, Inc.'s subcu drug delivery business, driven by ENHANZE technology, shows strong revenue growth with significant collaborations, but faces potential challenges post-2030 due ...

Wells Fargo analyst Mohit Bansal has maintained their neutral stance on HALO stock, giving a Hold rating yesterday.Stay Ahead of the ...

1 "We are pleased Opdivo Qvantig, which is co-formulated with our Enhanze drug delivery technology, is now FDA-approved as the first and only subcutaneously administered PD-1 inhibitor in the US ...

Biotechnology pioneer Halozyme has developed ENHANZE, a drug delivery technology that can enable and optimize the subcutaneous (SC) drug delivery of coadministered therapeutics. ENHANZE is based ...

"Halozyme is at the forefront of drug delivery innovation, fostering a high-growth and durable business underpinned by our proprietary ENHANZE drug delivery technology. This leadership position is ...

Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. The company has eight marketed partnered drugs based on this technology ...